ANITA ROTTER
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Clinical evaluation of the efficacy and safety of an active moisturizer-barrier repairer as an adjuvant treatment in atopic dermatitis in children(2017) PIRES, M. C.; VIDIGAL, M. R.; REIS, N. I. dos; SANTOS, L. R.; ROTTER, A.; TORLONI, L. B. O.Introduction: The use of moisturizers improves the skin barrier's function and might be useful in atopic dermatitis. Objectives: To assess the efficacy and safety of an active moisturizer-barrier repairer based on glycerin, erythritol, Imperata cylindrica and homarine as an adjuvant treatment in atopic dermatitis. Methods: Application of the moisturizer in children with mild to moderate atopic dermatitis for 1 month, with subjective and objective evaluations after 15 and 30 days. Results: Data from 35 children - 20 girls (57.15%), 15 boys (42.86%) / 26 Caucasians (74.29%), 6 mulattos (17.14%), 3 dark skinned (8.57%) - aged 1 to 10 years (mean age = 5.6) were analyzed. The values of the variables sleeping disorders, dryness, desquamation, pruritus and softness of the skin had significantly decreased on the 30th day of treatment as compared to the baseline. The objective evaluation of the severity using the Scoring Atopic Dermatitis severity index revealed a decrease to 9.30 from 25.27 (p < 0.0001). There was a reduction in the use of dexchlorpheniramine and hydrocortisone to 5.72% each on the 30th day, from 25.71% (p = 0.0233) and 34.29% (p = 0.0075) on the 15th day, respectively. Conclusions: The use of the moisturizer for 30 days improved the analyzed symptoms with a significant reduction in the Scoring Atopic Dermatitis severity index with decreased need for antihistamines and topical corticosteroids. The use of a suitable moisturizer was effective and safe as an adjuvant treatment for children with atopic dermatitis.
- Evaluation of plasma and urinary levels of vascular endothelial growth factor and matrix metalloproteinase-9 in patients with infantile hemangioma(2021) ROTTER, Anita; LIMA, Xinaida T.; OLIVEIRA, Zilda N. P.Background The pathogenesis of infantile hemangioma (IH) is not fully understood. It has been suggested that angiogenic factors increase in the proliferative stage, decreasing subsequently in the regression phase. Objectives To evaluate vascular endothelial growth factor (VEGF) and matrix metalloproteinase 9 (MMP-9) levels, according to infantile hemangioma (IH) growth stages and size, and to compare these levels in patients with IH and control subjects. Methods This cross-sectional study included 68 patients with IH and 25 control subjects. Plasma and urinary MMP-9 and VEGF levels were evaluated during proliferative and regression phases. These levels were correlated with tumor size measured by ultrasonography. Nonparametric tests were performed. Results Among 68 patients with IH, 55 (81%) were female. Age ranged from 1 to 40 months (median 7.0 months). There was no difference in plasma and urinary levels of VEGF and MMP-9 between patients and control subjects. There were no significant differences in these levels between IH patients younger or older than 12 months of age, as a cutoff between proliferative and involution phases. No significant correlation was observed between tumor size and levels of the markers (R P > 0.05 for all comparisons). Conclusion In our large sample, levels of VEGF and MMP-9 did not reflect the characteristic increased angiogenesis in patients with IH when compared to healthy subjects. In addition, these markers were not increased in the proliferative stage of the IH and did not correlate with tumor size.
- PHACE syndrome: clinical manifestations, diagnostic criteria, and management(2018) ROTTER, Anita; SAMORANO, Luciana Paula; RIVITTI-MACHADO, Maria Cecilia; OLIVEIRA, Zilda Najjar Prado; GONTIJO, BernardoInfantile hemangioma can be linked to other organ malformations. In 1996, PHACE syndrome was first defined as the association of large and segmental infantile hemangioma, usually on the face, head, or cervical region, with malformations of the posterior fossa of the brain, arterial anomalies of the central nervous system, coarctation of the aorta, cardiac defects, and ocular abnormalities. Over 300 cases of PHACE syndrome have been reported, and it is cconsidered one of the most common neurocutaneous vascular disorders in childhood. Knowledge of the features and locations of lesions that imply a greater risk of systemic involvement is crucial for the diagnosis and proper management of PHACE syndrome patients. This review highlights the diagnostic criteria for PHACE syndrome, the imaging workup for extracutaneous involvement, the treatment of infantile hemangioma, and the importance of a multidisciplinary approach in the management of these patients.
- Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol(2017) ROTTER, Anita; SAMORANO, Luciana Paula; LABINAS, Glaucia Helena de Oliveira; ALVARENGA, Juliana Gobbi; RIVITTI-MACHADO, Maria Cecilia; BOUER, Marcio; SANTOS, Paulo C. C.; SILVESTRE, Daniel A. M.; OLIVEIRA, Zilda Najjar Prado deBackgroundInfantile hemangiomas (IHs) are the most common benign vascular tumors of childhood. Propranolol is an effective drug in treating IH. A reliable and complementary instrument is necessary to evaluate IH response to propranolol in addition to clinical and photographic assessments. Ultrasonography is a simple and non-invasive technique that enables precise measurements of tumor size and contributes to objective follow-up. ObjectiveTo demonstrate the use of serial ultrasonography as an adjunctive tool for assessment of IH treatment with propranolol. Patients and methodsA retrospective study of 19 patients with IH treated with propranolol was conducted from January 2009 to March 2014. Data of individual IH volume at the beginning and at least 6 months after the onset of treatment and overall volume reduction by ultrasonographic measurement were obtained. ResultsWe observed a statistically significant IH volume reduction of approximately 0.51 cm(3). This volume corresponds to an average reduction of 47% in the final volume compared with the initial volume. ConclusionUltrasonographic measurements contribute to demonstrate tumor regression and IH response to propranolol. Thus, ultrasonography is an important instrument to guide therapeutic strategies.
- Propranolol for treatment of infantile hemangiomas(2013) MELO, Juliana Nakano de; ROTTER, Anita; RIVITTI-MACHADO, Maria Cecilia; OLIVEIRA, Zilda Najjar Prado deInfantile hemangioma is the most common vascular tumor in early childhood. Propranolol has been successfully used recently in a limited number of children with Infantile hemangioma. We present 6 cases of Infantile hemangioma, at a single dermatological center, which responded to oral propranolol with good results.
- Infantile hemangioma: pathogenesis and mechanisms of action of propranolol(2017) ROTTER, Anita; OLIVEIRA, Zilda Najjar Prado deInfantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Data source: The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. Conclusions: The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors, including tissue inhibitors of matrix metalloproteinases, increase. Since 2008, propranolol has become the drug of choice in the treatment of IH, targeting vascular tone, angiogenesis, and apoptosis. Current insights into the pathogenesis of IH allow for the development of new therapeutic strategies.